SEC accuses Merck exec of insider trading

In a civil suit filed in Philadelphia, the SEC accused James Self, 45, an executive director at Merck, of feeding his business school buddy and former hedge fund manager Stephen Goldfield, 46, the details of a 2007 Merck deal to buy drug firm MedImmune. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.